PHASE-1 CLINICAL-TRIAL OF COMBINED THERAPY WITH VINBLASTINE (NSC-49842), BLEOMYCIN (NSC-125066), AND CIS-DICHLORODIAMMINEPLATINUM(II) (NSC-119875)

  • 1 January 1976
    • journal article
    • research article
    • Vol. 60 (1), 91-97
Abstract
Seventeen patients with various histologic types of incurable malignant disease were treated with a combination of vinblastine, bleomycin and cis-dichlorodiammineplatinum (II). Creatinine and blood urea N elevations were noted but were not of a severe degree. White blood cell and platelet count depressions were seen and appeared to be cumulative, though not life-threatening. Tinnitus and high-frequency hearing loss were noted. Tumor regression was seen in 1 patient with adenocarcinoma of the lung and in 1 patient with a testicular tumor. This appears to be a manageable drug combination with frequent monitoring of renal, hematopoietic, pulmonary and auditory function. A phase II study establishing the therapeutic efficacy of this combination in advanced testicular neoplasms is indicated.